

Prof. Hughes, Prof. Nowak and Prof. Germain invite you to a Satellite Symposium at SSIEM 2024

# Can we meet the challenges of living well with Fabry disease?



September 3, 2024  
12:45–13:45



Laurel room  
Level -1



## JOIN US

at this symposium where our experts empower you to navigate the complexities of Fabry disease across patients' lifespans and aim to optimize management strategies.



**Prof. Derrallynn Hughes, MD**

Royal Free Hospital, NHS Foundation Trust and  
University College London  
London, United Kingdom



**Prof. Albina Nowak, MD**

Clinic for Endocrinology, Diabetology and  
Clinical Nutrition, University Hospital  
Zurich, Switzerland



**Prof. Dominique P. Germain, MD PhD**


Paris Saclay University / University of Versailles - St Quentin en Yvelines (UVSQ)  
Division of Medical Genetics, UFR des Sciences de la Santé Simone Veil  
Montigny, France



# Detailed agenda

September 3, 12:45-13:45 GMT

LENGTH	TOPIC	SUGGESTED CONTENT	SPEAKER
12:45-12:47	<b>Introduction</b>	<ul style="list-style-type: none"> <li>Outline symposium concept and objectives, and introduce faculty</li> </ul>	Derralynn Hughes (United Kingdom)
12:47-13:02	<b>Evolution of Fabry disease across the patient's lifespan</b> <u>Objectives:</u> <ul style="list-style-type: none"> <li>Review the clinical course of Fabry disease with consideration of the long-term benefits of ERT using 20-year results from FOS and other registry data</li> <li>Summarize life events that may influence the course of disease, the importance of monitoring patients for the occurrence of such events, and how they might influence management</li> </ul>	<ul style="list-style-type: none"> <li>Outline evolution of disease complications and comorbidities over a patient's lifespan</li> <li>Summarize long-term effects of disease and its treatment on organ function (e.g., heart, kidney)</li> <li>Present FOS accomplishments</li> <li>Describe considerations in the management of elderly patients with Fabry disease</li> </ul>	Albina Nowak (Switzerland)
13:02-13:17	<b>The spectrum of Fabry disease: Implications for patient management</b> <u>Objectives</u> <ul style="list-style-type: none"> <li>Consider the phenotypic spectrum for patients with Fabry disease and how it may be related to genotype</li> <li>Summarize evidence relating genotype to patient's responses to treatment</li> </ul>	<ul style="list-style-type: none"> <li>Review classic vs late-onset phenotypes and associated genotypes</li> <li>Implications of most recent FOS results with respect to the importance of early diagnosis and initiation of treatment</li> <li>Consider the immune response to ERT and how it may vary as a function of genotype and residual <math>\alpha</math>-galactosidase A</li> </ul>	Derralynn Hughes (United Kingdom)
13:17-13:32	<b>Fabry in females: Overlooked, undertreated</b> <u>Objectives</u> <ul style="list-style-type: none"> <li>Address baseline evaluation and monitoring in females with Fabry disease</li> <li>Describe the impact of life events (e.g., menarche, child-bearing, menopause) on disease symptoms and severity</li> </ul>	<ul style="list-style-type: none"> <li>Monitoring asymptomatic patients</li> <li>Criteria for initiation of therapy</li> <li>Review the bidirectional relationship between the severity of Fabry disease, signs and symptoms, and specific life events in women with Fabry disease</li> </ul>	Dominique Germain (France)
13:32-13:42	<b>Questions and answers</b>		All
13:42-13:45	<b>Summary: What Living Well Means for Patients with Fabry Disease</b>		Derralynn Hughes (United Kingdom)



# Short agenda

TIME	LENGTH	PRESENTATION	FACULTY
12:45-12:47	2 minutes	Welcome, introductions, and meeting objectives	Derralynn Hughes
12:47-13:02	15 minutes	Evolution of Fabry disease across the patient's lifespan	Albina Nowak
13:02-13:17	15 minutes	The spectrum of Fabry disease: Implications for patient management	Derralynn Hughes
13:17-13:32	15 minutes	Fabry in females: Overlooked, undertreated	Dominique Germain
13:32-13:42	10 minutes	Questions and answers	All
13:42-13:45	3 minutes	Summary: What Living Well Means for Patients with Fabry Disease	Derralynn Hughes

